Stock Events

Stock Events

Tango Therapeutics 

$26.06
28
+$0.62+2.44% 14:30 Today

Statistics

Day High
26.34
Day Low
25.67
52W High
34.39
52W Low
6.25
Volume
338,475
Avg. Volume
3,827,153
Mkt Cap
4.39B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.37
-0.2
-0.03
0.14
Expected EPS
-0.348054
Actual EPS
N/A

Financials

-162.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
62.38MRevenue
-101.59MNet Income

Analyst Ratings

42.80Average Price Target
The highest estimate is 69.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNGX. It's not an investment recommendation.
NVIDIA
9
NVDA
Apple
7
AAPL
Microsoft
6
MSFT
Coca-Cola
6
KO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Tango Therapeutics' approach to targeting cancer.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is a leading developer of CRISPR gene editing, directly competing in the genetic medicine space.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine operates in the CRISPR gene editing sector, offering technologies that could rival Tango's cancer therapies.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics focuses on base editing, a form of gene editing that could offer alternative treatments to those developed by Tango.
Allogene Therapeutics
ALLO
Mkt Cap708.26M
Allogene Therapeutics is focused on allogeneic CAR T-cell therapies, which could be in direct competition with Tango's cancer treatment approaches.
Fate Therapeutics
FATE
Mkt Cap307.94M
Fate Therapeutics is working on programmed cellular immunotherapies, which could compete with Tango's cancer treatment strategies.
Novartis
NVS
Mkt Cap286.78B
Novartis is a large pharmaceutical company with a broad portfolio, including advanced therapies that could compete with Tango's cancer treatments.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, with its acquisition of Kite Pharma, has a strong presence in cell therapy for cancer, competing with Tango Therapeutics.

About

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Show more...
CEO
Malte Peters
Employees
137
Country
United States
ISIN
US87583X1090

Listings

XNAS
US
TNGX
BOATS
BOATS
TNGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Tango Therapeutics stock price today?▼
The current price of TNGX is $26.06 USD — it has increased by +2.44% in the past 24 hours. Watch Tango Therapeutics stock price performance more closely on the chart.
What is Tango Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tango Therapeutics stocks are traded under the ticker TNGX.
Is Tango Therapeutics stock price growing?▼
TNGX stock has risen by +1.68% compared to the previous week, the month change is a -8.93% fall, over the last year Tango Therapeutics has showed a +273.71% increase.
What is Tango Therapeutics market cap?▼
Today Tango Therapeutics has the market capitalization of 4.39B
When is the next Tango Therapeutics earnings date?▼
Tango Therapeutics is going to release the next earnings report on November 10, 2026.
What were Tango Therapeutics earnings last quarter?▼
TNGX earnings for the last quarter are -0.37 USD per share, whereas the estimation was -0.32 USD resulting in a -16.64% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tango Therapeutics revenue for the last year?▼
Tango Therapeutics revenue for the last year amounts to 62.38M USD.
What is Tango Therapeutics net income for the last year?▼
TNGX net income for the last year is -101.59M USD.
How many employees does Tango Therapeutics have?▼
As of August 19, 2026, the company has 137 employees.
In which sector is Tango Therapeutics located?▼
Tango Therapeutics operates in the Health & Wellness sector.
When did Tango Therapeutics complete a stock split?▼
Tango Therapeutics has not had any recent stock splits.
Where is Tango Therapeutics headquartered?▼
Tango Therapeutics is headquartered in BOSTON, United States.